0914 GMT - Reckitt's core business is strong, with brands including Nurofen and Durex part of a smaller but faster-growing business, Barclays analysts write as they raise the rating on the stock to overweight from equal weight. Better performance in developed markets, as well as growth potential in the intimate-wellness space, also bode well for the U.K. consumer-goods group, they say. "'Core Reckitt' is a business with attractive margins and a particularly consistent 60% gross margin profile," the analysts write. Barclays raises the stock's target price to 70 pounds from 63 pounds. Shares are up 1.9% at 59.64 pounds. (josephmichael.stonor@wsj.com)

(END) Dow Jones Newswires

December 01, 2025 04:14 ET (09:14 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.